SCHEMBL6785602

SCHEMBL6785602

Fc1ccc(-c2cccc3c2C2CCNCCC2N3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.40
HTR1A P08908 5/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 3/20 0.36
HRH1 P35367 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
HTR2A P28223 3/20 0.34
HTR2C P28335 3/20 0.34
JAK2 O60674 1/20 0.34
JAK3 P52333 1/20 0.34
PTK2 Q05397 1/20 0.34
DRD2 P14416 2/20 0.33
KCNH2 Q12809 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785604 1.00 HTR7 (0.40) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785282 0.88 CHRM3 (0.35) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785280 0.88 CHRM3 (0.35) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6791319 0.88 HRH1 (0.42) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6791321 0.88 HRH1 (0.42) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6782255 0.87 PLAT (0.39) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6782257 0.87 PLAT (0.39) HTR7HTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6786365 0.86 KDM1A (0.36) HRH1LMNATSHRHTR2CKCNH2
SCHEMBL6786361 0.86 KDM1A (0.36) HRH1LMNATSHRHTR2CKCNH2
SCHEMBL6785250 0.86 CREBBP (0.42) LMNATSHRHTR2ADRD2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828314-B2 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity PFIZER 2004-12-07 US disclosed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 US disclosed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 US disclosed
EP-1319005-A2 SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-06-18 EP disclosed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 US disclosed
WO-2002024700-A2 SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives HTR5A, HTR1A, HTR4 HTR7 14/4885HTR1A 2/4885SLC6A2 104/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 HTR7 14/4885HTR1A 2/4885SLC6A2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.